SG172974A1 - Carboxamide compounds and methods for using the same - Google Patents

Carboxamide compounds and methods for using the same Download PDF

Info

Publication number
SG172974A1
SG172974A1 SG2011050861A SG2011050861A SG172974A1 SG 172974 A1 SG172974 A1 SG 172974A1 SG 2011050861 A SG2011050861 A SG 2011050861A SG 2011050861 A SG2011050861 A SG 2011050861A SG 172974 A1 SG172974 A1 SG 172974A1
Authority
SG
Singapore
Prior art keywords
alkyl
haloalkyl
compound according
substituted
heterocycloalkyl
Prior art date
Application number
SG2011050861A
Other languages
English (en)
Inventor
Ihab S Darwish
Hui Hong
Rajinder Singh
Xiang Xu
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of SG172974A1 publication Critical patent/SG172974A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG2011050861A 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same SG172974A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14798209P 2009-01-28 2009-01-28
PCT/US2010/022411 WO2010088392A1 (en) 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same

Publications (1)

Publication Number Publication Date
SG172974A1 true SG172974A1 (en) 2011-08-29

Family

ID=42061132

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011050861A SG172974A1 (en) 2009-01-28 2010-01-28 Carboxamide compounds and methods for using the same

Country Status (17)

Country Link
US (2) US8362235B2 (cg-RX-API-DMAC7.html)
EP (1) EP2391616B1 (cg-RX-API-DMAC7.html)
JP (1) JP5658688B2 (cg-RX-API-DMAC7.html)
KR (1) KR101693061B1 (cg-RX-API-DMAC7.html)
CN (1) CN102365275B (cg-RX-API-DMAC7.html)
AU (1) AU2010208247B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1007287B8 (cg-RX-API-DMAC7.html)
CA (1) CA2750835C (cg-RX-API-DMAC7.html)
EA (1) EA022083B1 (cg-RX-API-DMAC7.html)
ES (1) ES2581678T3 (cg-RX-API-DMAC7.html)
IL (1) IL214203A (cg-RX-API-DMAC7.html)
MX (1) MX2011007639A (cg-RX-API-DMAC7.html)
NZ (1) NZ594556A (cg-RX-API-DMAC7.html)
SG (1) SG172974A1 (cg-RX-API-DMAC7.html)
UA (1) UA106600C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010088392A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105215B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
HUE052110T2 (hu) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
US9409884B2 (en) 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
US20150087673A1 (en) * 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US20160214967A1 (en) 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
EP3737361A4 (en) 2018-01-11 2021-08-25 Centaurus Therapeutics INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
KR100579792B1 (ko) 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
AU2001287898A1 (en) * 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
DE602006021591D1 (de) 2006-12-11 2011-06-09 Genetics Co Inc Aromatische 1,4-DI-Carboxylamide und deren Verwendung
ES2627221T3 (es) * 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2231666B1 (en) * 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009132136A1 (en) * 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8796254B2 (en) 2010-03-31 2014-08-05 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds

Also Published As

Publication number Publication date
ES2581678T3 (es) 2016-09-06
US20130131078A1 (en) 2013-05-23
KR20110119755A (ko) 2011-11-02
US8362235B2 (en) 2013-01-29
EA201170979A1 (ru) 2012-02-28
EP2391616A1 (en) 2011-12-07
IL214203A (en) 2015-01-29
CA2750835C (en) 2018-09-04
HK1164860A1 (zh) 2012-09-28
NZ594556A (en) 2013-11-29
CA2750835A1 (en) 2010-08-05
IL214203A0 (en) 2011-08-31
ZA201105215B (en) 2012-09-26
CN102365275A (zh) 2012-02-29
JP2012516349A (ja) 2012-07-19
EP2391616B1 (en) 2016-03-30
BRPI1007287B1 (pt) 2021-03-09
KR101693061B1 (ko) 2017-01-04
JP5658688B2 (ja) 2015-01-28
WO2010088392A1 (en) 2010-08-05
MX2011007639A (es) 2011-09-15
AU2010208247A1 (en) 2011-08-11
EA022083B1 (ru) 2015-10-30
UA106600C2 (uk) 2014-09-25
US8846600B2 (en) 2014-09-30
AU2010208247B2 (en) 2015-06-18
US20100190802A1 (en) 2010-07-29
CN102365275B (zh) 2014-09-24
BRPI1007287B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
EP2598483B1 (en) Ampk-activating heterocyclic compounds and methods for using the same
EP2391616B1 (en) Carboxamide compounds and methods for using the same
EP2276761B1 (en) Carboxamide compounds for the treatment of metabolic disorders
EP2231666B1 (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2674237C (en) N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
EP2231600B1 (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP3500558B1 (en) Benzimidazole direct ampk activators
HK1164860B (en) Carboxamide compounds and methods for using the same
HK1152939B (en) Carboxamide compounds for the treatment of metabolic disorders
HK1148524B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
HK1148525B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders